The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.